Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
GO:000689215 | Esophagus | ESCC | post-Golgi vesicle-mediated transport | 82/8552 | 104/18723 | 4.00e-12 | 1.55e-10 | 82 |
GO:009887615 | Esophagus | ESCC | vesicle-mediated transport to the plasma membrane | 99/8552 | 136/18723 | 1.13e-10 | 3.39e-09 | 99 |
GO:000689315 | Esophagus | ESCC | Golgi to plasma membrane transport | 48/8552 | 60/18723 | 5.11e-08 | 9.16e-07 | 48 |
GO:00610254 | Esophagus | ESCC | membrane fusion | 98/8552 | 163/18723 | 1.39e-04 | 9.41e-04 | 98 |
GO:00481936 | Liver | NAFLD | Golgi vesicle transport | 66/1882 | 296/18723 | 3.66e-10 | 9.30e-08 | 66 |
GO:00068925 | Liver | NAFLD | post-Golgi vesicle-mediated transport | 31/1882 | 104/18723 | 1.70e-08 | 2.03e-06 | 31 |
GO:00068934 | Liver | NAFLD | Golgi to plasma membrane transport | 19/1882 | 60/18723 | 3.60e-06 | 1.42e-04 | 19 |
GO:00988765 | Liver | NAFLD | vesicle-mediated transport to the plasma membrane | 30/1882 | 136/18723 | 2.76e-05 | 7.39e-04 | 30 |
GO:19907786 | Liver | NAFLD | protein localization to cell periphery | 56/1882 | 333/18723 | 8.29e-05 | 1.69e-03 | 56 |
GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
GO:199077821 | Liver | HCC | protein localization to cell periphery | 200/7958 | 333/18723 | 6.07e-11 | 2.23e-09 | 200 |
GO:000689221 | Liver | HCC | post-Golgi vesicle-mediated transport | 77/7958 | 104/18723 | 6.14e-11 | 2.24e-09 | 77 |
GO:009887621 | Liver | HCC | vesicle-mediated transport to the plasma membrane | 92/7958 | 136/18723 | 2.57e-09 | 7.07e-08 | 92 |
GO:000689321 | Liver | HCC | Golgi to plasma membrane transport | 44/7958 | 60/18723 | 1.24e-06 | 1.81e-05 | 44 |
GO:0061025 | Liver | HCC | membrane fusion | 88/7958 | 163/18723 | 1.98e-03 | 1.00e-02 | 88 |
GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
GO:199077816 | Oral cavity | OSCC | protein localization to cell periphery | 190/7305 | 333/18723 | 1.46e-11 | 5.13e-10 | 190 |
GO:00068929 | Oral cavity | OSCC | post-Golgi vesicle-mediated transport | 71/7305 | 104/18723 | 1.37e-09 | 3.33e-08 | 71 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RABEP1 | SNV | Missense_Mutation | | c.2578N>G | p.Pro860Ala | p.P860A | Q15276 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-A2-A259-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
RABEP1 | SNV | Missense_Mutation | novel | c.1346N>A | p.Ser449Tyr | p.S449Y | Q15276 | protein_coding | deleterious(0.03) | possibly_damaging(0.453) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RABEP1 | SNV | Missense_Mutation | rs773135833 | c.376N>T | p.Arg126Cys | p.R126C | Q15276 | protein_coding | tolerated(0.21) | benign(0.017) | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
RABEP1 | insertion | Frame_Shift_Ins | novel | c.2451_2452insGAAAATGT | p.Gln818GlufsTer8 | p.Q818Efs*8 | Q15276 | protein_coding | | | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RABEP1 | insertion | Nonsense_Mutation | novel | c.2452_2453insATTCCATTTGACTGATGTATCAAATCCTA | p.Gln818HisfsTer4 | p.Q818Hfs*4 | Q15276 | protein_coding | | | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RABEP1 | deletion | In_Frame_Del | | c.2253_2261delNNNNNNNNN | p.Val753_Lys755del | p.V753_K755del | Q15276 | protein_coding | | | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
RABEP1 | deletion | Frame_Shift_Del | novel | c.1951delA | p.Ser651ValfsTer32 | p.S651Vfs*32 | Q15276 | protein_coding | | | TCGA-UL-AAZ6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | herceptin | SD |
RABEP1 | SNV | Missense_Mutation | rs375323638 | c.1063N>A | p.Glu355Lys | p.E355K | Q15276 | protein_coding | tolerated(0.17) | benign(0.058) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RABEP1 | SNV | Missense_Mutation | novel | c.2299C>G | p.Gln767Glu | p.Q767E | Q15276 | protein_coding | tolerated(0.92) | benign(0.003) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RABEP1 | SNV | Missense_Mutation | | c.1060C>G | p.Gln354Glu | p.Q354E | Q15276 | protein_coding | tolerated(0.6) | benign(0.001) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | | lithium | LITHIUM | 28694205 |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | | amisulpride | AMISULPRIDE | 28694205 |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | | valproic acid | | 28694205 |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | | risperidone | RISPERIDONE | 28694205 |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | | olanzapine | OLANZAPINE | 28694205 |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | | mirtazapine | MIRTAZAPINE | 28694205 |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | | clozapine | CLOZAPINE | 28694205 |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | | aripiprazole | ARIPIPRAZOLE | 28694205 |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | | quetiapine | QUETIAPINE | 28694205 |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | | paliperidone | PALIPERIDONE | 28694205 |